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Diabetes 2, once reserved for those who are aging, is now
rampant in adolescents in the USA. Obesity is the culprit
brought on by poor eating habits, lack of exercise and a
general malaise paradoxically due to wealth and not pov-
erty (at least material). In our penultimate issue of eCAM
supported by OUP, I aim to show certain advancements
in evidence-based approaches. Diabetes is a condition in
persons who have a high blood sugar (glucose) level
either because the body does not produce enough insulin
or because body cells do not properly respond to the
insulin that is produced. Insulin is a hormone produced
in the pancreas which enables body cells to absorb glu-
cose, and to convert into energy. If the body cells do not
absorb glucose, the glucose accumulates in the blood
(hyperglycemia), leading to vascular, nerve and other
complications. Serious long-term complications include
cardiovascular disease, chronic renal failure and retinal
damage. Adequate treatment of diabetes is thus import-
ant as well as blood pressure control and lifestyle factors
such as smoking cessation and maintaining a healthy
body weight. As of 2000, at least 171 million people
worldwide suffer from diabetes, or 2.8% of the popula-
tion. Type 2 diabetes is by far the most common, affect-
ing 90–95% of the US’s diabetes population.
Guo and colleagues (1) propose a hypothesis. They sug-
gest one novel vanadium complex of vanadium-enriched
Cordyceps sinensis (VECS), which is beneficial in prevent-
ing depression in diabetes and it can influence the long-
term course of glycemic control. Vanadium compounds
imitate the action of insulin, and this mimicry may have
further favorable effects on levels of treatment satisfac-
tion and mood. C. sinensis has an antidepressant-like
activity, and attenuates the diabetes-induced increase in
blood glucose concentrations. Thus, they suggest that the
VECS may be a potential strategy for a more contem-
porary treatment of depression and diabetes through the
co-effect of C. sinensis and vanadium. In an animal
model, to test the validity of this hypothesis, investiga-
tors can examine blood glucose levels, which in turn are
measured by swimming and climbing behavior in
streptozotocin-induced hyperglycemic rats. This strongly
supports the use of animal models to help understand
disease.
In contrast to the basic science approach, Aljasir et al.
(2) have reviewed a clinical strategy, and that is Yoga
practice for the management of diabetes in adults. All
randomized controlled clinical trials comparing yoga
practice with other types of intervention or with regular
practice or both were examined. Two independent re-
viewers assessed each study for quality. The mean differ-
ence was used for summarizing the effect of each study
outcome with 95% confidence intervals. Results show
improvement in outcomes among patients with diabetes
but these were among short-term or immediate diabetes
outcomes; not all were statistically significant, leaving in-
conclusive results and insignificant long-term outcomes.
Therefore no adverse effects were reported in any of the
studies. Short-term benefits for patients with diabetes
may be achieved by practicing yoga. Further research is
needed in this area. Factors like quality of the trials and
other methodological concerns should be improved by
large randomized control trials with allocation conceal-
ment to assess the effectiveness of yoga on diabetes.
Although promising, definitive recommendations for
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properly cited.physicians to encourage their patients to practice yoga
are not yet conclusive. We need more evidence-based
approaches.
As a basic science approach, Choi et al. (3) analyzed
diabetic nephropathy—one of the most frequent and ser-
ious complications of diabetes. Soybeans have been
shown to reduce urinary albumin excretion and total
cholesterol in non-diabetic patients with nephrotic syn-
drome. However, because reports focusing specifically
on diabetic nephropathy are scarce and the available re-
sults are inconsistent, soybean consumption was found to
reduce urinary protein excretion in type 1 diabetic pa-
tients with diabetic nephropathy, whereas it elicited an
increase in urinary protein excretion when soybeans
were consumed by type 2 diabetic patients. Again,
animal models are advantageous. Male Sprague–Dawley
rats were assigned to one of three groups: control, dia-
betic with red chow diet and diabetic with soybean diet.
For histological examination, the expression of osteopon-
tin (OPN) and aquaporin (AQP), renal function and
hemoglobin A1c were evaluated at the end of the study.
Improvements in glomerular and tubulointerstitial lesions
were demonstrated in the diabetic rat group given a soy-
bean diet. OPN Costeopontiu and AQP aquaporin
expression were suppressed in the kidneys of diabetic
rats that consumed the soybean diet. With these results,
a tentative conclusion is proposed. Soybeans may prevent
weight loss and morphological disruption of the kidney
and may also improve glycemic control. Thus long-term
control of blood glucose levels using a soybean diet could
prevent the progression of diabetes, and therefore,
nephropathy might be prevented.’’ (3).
Finally another clinical approach shows promise.
‘‘Satureja khuzestanica is an endemic plant widely distrib-
uted in the Southern part of Iran. It has antioxidant
properties and seems to be useful in diseases related to
oxidative stress such as diabetes and hyperlipidemia. As a
test, they investigated the effect of S. khuzestanica
supplement on metabolic parameters of hyperlipidemic
patients with diabetes. Twenty-one hyperlipidemic
patients with diabetes were randomized in a double
blind, placebo-controlled clinical trial to receive either
S. khuzestanica (tablets contain 250mg dried leaves) or
placebo once a day for 60 days. Blood samples were ob-
tained at baseline at the end. Samples were analyzed for
levels of glucose, total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglyceride, creatinine, thiobarbituric
acid reactive substances (TBARS) as marker of lipid per-
oxidation and ferric reducing ability [total antioxidant
power, (TAP)]. Treatment of patients by S. khuzestanica
for 60 days induced significant decrease in total
cholesterol (P=0.008) and LDL-cholesterol (P=0.03)
while increased HDL-cholesterol (P=0.02) and TAP
(P=0.007) in comparison with the baseline values.
S. khuzestanica did not alter blood glucose, triglyceride,
creatinin and TBARS levels. In comparison with baseline
values, no significant change was observed in blood
glucose, total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglyceride, creatinine, TBARS and TAP in
placebo-treated group. They therefore recommended the
usage of S. khuzestanica as a supplement to drug regimen
of diabetic type 2 patients with hyperlipidemia’’ (4).
These four approaches to a growing health problem of
enormous proportions have reached an avenue for pro-
viding evidence-based results. eCAM will remain com-
mitted to critical thinking and strategies that will move
us closer to self awareness, personal commitment and
control. These two points that fuel research should, in
the next few years, offer some relief to this paradoxical
condition fueled by personal negligence.
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